#3-14E. Engineering Tolerance: A Probiotic Approach to Peanut Allergy (J Allergy Clin Immunol, 2026)

With food allergies placing an immense burden on healthcare systems, the search for safer alternatives to conventional oral immunotherapy is critical. In this episode, we examine a novel strategy utilizing Escherichia coli Nissle 1917, genetically engineered to surface-display both the major peanut allergen Ara h 2 and an inhibitory Siglec ligand. By targeting the inhibitory receptor CD22 on B cells, this "living therapeutic" aims to suppress allergen-specific immune responses directly within the gut. The study establishes a crucial proof-of-concept: oral administration of these modified probiotics significantly reduced anaphylactic responses and lowered serum IgE levels in sensitized mice, offering a potential non-invasive alternative to complex nanoparticle therapies. However, critical appraisal requires noting that these results are derived from a murine model using a single allergen; thus, efficacy against the complex, multi-allergen nature of human peanut allergy remains to be proven. For physicians, this research signals a promising shift toward targeted B-cell depletion strategies that could eventually provide safer, scalable desensitization options for patients who cannot tolerate current protocols.

Citation: Zilic JM, Keys TG, Hennet T. Decreased anaphylaxis by probiotic Escherichia coli overexpressing Siglec ligand and peanut allergen. J Allergy Clin Immunol. 2026. DOI: 10.1016/j.jaci.2025.09.022

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.